4th Annual Generic Drug Forum - Future Trends in the Generic Drug Industry
4th Annual Generic Drug Forum April 6-7, 2006 | Washington, DC | There are many issues that Generic Drug manufacturers face in expanding their product offerings and taking them to market. When looking at the marketing and business development side of the generic drug market, there are a lot of challenges that companies are facing. It becomes increasingly difficult for generic drug manufacturers to make decisions on what drug would be the best to move forward into production. It is also important to know what the branded pharmaceutical companies are planning for future product developments, as well as with their current branded therapies, as many companies, when considering the expiry of their blockbusters’ patent, will consider re-launching or redeveloping the therapy in order to elongate or continue the brand. Reaching patients and creating access to generic drugs has become one of the largest challenges faced by the industry as people, in general, do not consider them to be “bioequivalent” to their branded partners. From the production side, there are also a number of important issues to consider. Generic drug manufacturers must insure that the drugs they are producing are exact replicas of the branded drugs in accordance with FDA regulations. This is of increasing importance, as many branded drugs are of an increasingly complex nature, and thus require additional manufacturing quality assurance programs. In some cases, generic drug manufacturers are being told that they need to conduct small to mid-scale clinical trials to prove the efficacy of their products! And, of course, there is increasing FDA surveillance, resulting in large-scale recalls and, to a smaller extent, the liquidation of generic houses. At this conference, we will address these issues through the presentation of case studies and the conducting of panel discussions highlighting the best practices of leading generic drug companies.
Washington (PRWEB) February 9, 2006
The Bush Administration has deliberately advocated for the production and use of generic drugs to keep down spiraling healthcare costs. A policy, which has led to increasing use of generic therapeutics worldwide with generic drugs, capturing 14% of the global healthcare market, and revenues of $58 billion. The imminent patent expirations of many major drugs; 42 in the period 2005 to 2009 will provide a critical growth stimulus for the generic drug companies. Therefore a possible ripe future exists but one not with out challenges.
Marcus evans’ 4th Annual Generic Drug Forum April 6-7, 2006, will address issues, which are occurring in evolving generic drug industry through the presentation of case studies and the conducting of panel discussions highlighting the best practices of leading generic drug companies, which will lead to that ripe future in the generic drug Industry. Topics of interest include, ‘Empowering Generic Drug Companies against the Trend of Branded Patent Extensions’, Shashank Upadhye, Esq., VP & Counsel, Sandoz; ‘Anticipating the Future of the generic Drug Industry: What will the Tevas and the Mylans Do Next?’ Peter Ballard, Managing Director, Genus Pharmaceuticals and‘ Sustaining Competitive Markets in the Face of Authorized Generics’, Jake Hansen, VP, Government Affairs, Barr Laboratories and ‘Embracing the Modernization and its Implications for the Generic Drug Industry’ Shawn Brown, Director Policy, Generic Pharmaceutical Association.
Experts from Ranbaxy, Teva Sicor, Generamedix, Clay-park Laboratories, Elite Pharmaceuticals, Taro Pharmaceuticals, RxElite, United Research Laboratories, Pliva, Roxane Laboratories, Generamedix and FDA News will also share further industry perspectives.
About marcus evans
Marcus evans, one of the world’s leading business information companies, is dedicated to the provision of global business intelligence and information to assist in strategic and effective decision-making. Established in 1983, the company’s international network of offices creates major sector-focused events for business learning and networking opportunities across a variety of industries and professions.
###
